Beta-glucans are naturally occurring polysaccharides that exert important immunostimulatory activities. In the present study, we evaluated whether beta-glucans could modulate the development and the course of systemic lupus erythematosus (SLE). To this aim, we employed the classical model of SLE represented by the F1 hybrid between the NZB and NZW mouse strains which develop severe lupus-like phenotypes comparable to that of SLE patients. The administration of beta-glucan was associated to a more aggressive development of the disease and a worse prognosis, as observed from the clinical, biochemical and histopathological data. This finding implies that restraint should be practised in the possible use of beta-glucans as immunomodulators in human therapy in the context of SLE.
|Digital Object Identifier (DOI):||10.1177/0961203314522333|
|Codice identificativo ISI:||WOS:000337296000010|
|Codice identificativo Scopus:||2-s2.0-84896127472|
|Appare nelle tipologie:||1.1 Articolo in rivista|